Introduction: Thymic epithelial tumors (TETs) are rare intrathoracic malignancies that are categorized histologically according to the WHO classification, which was recently updated in 2015 on the basis of a consensus statement of the International Thymic Malignancy Interest Group (ITMIG); at the same time, the standard Masaoka-Koga staging system is scheduled to be replaced by the eighth edition of the TNM staging classification by the American Joint Committee on Cancer/Union for International Cancer Control consortium. Our objectives were to analyze the feasibility of assessing ITMIG consensus major and minor morphological and immunohistochemical criteria and the eighth edition of the TNM staging classification in a routine practice setting.
Introduction
Thymic epithelial tumors (TETs) are rare intrathoracic malignancies that are categorized histologically according to the WHO classification, 1 which was recently updated in 2015 on the basis of a consensus statement of the International Thymic Malignancy Interest Group (ITMIG) published in 2014. 2, 3 The classification distinguishes thymomas from thymic carcinomas (TCs); thymomas are further subdivided into different types (A, AB, B1, B2, and B3) based on the morphological features of epithelial tumor cells (polygonal or spindle cells), the relative proportion of the nontumoral lymphocytic component (decreasing from type B1 to B3), and resemblance to normal thymic architecture. [1] [2] [3] TCs are similar to their extrathymic counterpart, and the most frequent subtype is squamous cell carcinoma. Although the interobserver reproducibility of the WHO classification has been questioned over time, [4] [5] [6] the ITMIG consensus statement proposes major and minor morphological and immunohistochemical (IHC) criteria to better individualize each TET entity; these criteria were defined on the basis of a series of 58 prototypic and difficult-to-classify TETs. 2 TETs are routinely staged according to the MasaokaKoga staging system, which is a strong predictor of overall survival (OS). [7] [8] [9] [10] Masaoka-Koga staging is a surgical pathology system that is assessable only after surgical resection. A unique feature of TETs is that the WHO classification is correlated with stage at diagnosis, what may explain its reported prognostic value. 1, 11, 12 The International Association for the Study of Lung Cancer Staging Prognostic Factors Committee, together with ITMIG, recently proposed a TNM-based staging system for thymic malignancies that is based on OS analyses of a retrospective international database of more than 10,000 cases 13 ; the proposal was adopted in the eighth TNM staging classification by the American Joint Committee on Cancer/Union for International Cancer Control consortium. 14 In this staging system, all Masaoka stage I and II and some Masaoka stage III TETs are merged with stage I tumors on the basis of their similar prognosis; TNM stage II is defined by pericardium invasion; and TNM stage III tumors are further subdivided into two groups (T3 and T4), aiming at providing more help in formalizing resectability, a major driver of the treatment strategy in advanced TETs. 9, 13, 14 Here we took advantage of a surgical series of 188 TETs to (1) analyze the feasibility of assessing ITMIG consensus major and minor morphological and IHC criteria in a routine practice setting and the diagnostic performance of those criteria for TETs histological subtyping and (2) assess the feasibility and relevance of the eighth edition of the TNM staging classification with regard to the Masaoka-Koga staging system.
Material and Methods

Study Design
This study was conducted at the Louis-Pradel Hospital, Hospices Civils de Lyon, a national expert center for the management of TETs that is recognized by the French National Cancer Institute through the appointment in 2012 of RYTHMIC (network for thymic malignancies) network as part of its rare cancer program.
The study consisted of pathological review of 188 TETs, which were diagnosed in 181 patients between January 2000 and December 2014 at our center, to assess histological diagnosis according to the WHO classification, 1, 3 ITMIG consensus major and minor criteria, 2 and stage according to Masaoka-Koga 8 and the eighth edition of the TNM staging classification.
14 IHC stainings from the initial assessment and additional stainings were performed as per ITMIG consensus. 2 Review of clinical files was conducted to retrieve patients' characteristics, including preoperative imaging, operative reports, and follow-up.
Pathological Review
Consecutive cases with a diagnosis of TET were selected from the prospective registry of the Pathological Department of Pathology of Louis-Pradel Hospital. From a total of 229 cases, material was available for 195 cases, including 167 cases with nonmixed histological features, and 21 cases with mixed histological features but predominant subtype; seven cases with mixed TET were excluded to avoid complex analysis of histological criteria. Among the 188 cases that were included, 143 cases were from patients operated on in our center, and 45 were cases sent from outside the center for expertise. For patients who underwent surgical or percutaneous biopsy before resection of the tumor, only surgical specimens were reviewed. Pathological review was conducted by two thoracic pathologists, a senior pathologist (L. C.) and a junior pathologist (A. M.), by consensus. Paraffin blocks with formalin-fixed or alcohol, formalin, and acetic acid-fixated tissue and hematoxylin-eosin-saffron slides were available for all cases.
Review of ITMIG Consensus Major and Minor Morphological Criteria
ITMIG consensus major and minor morphological and IHC criteria were defined as per Marx et al. 2 (Supplementary Table 1) .
Major criteria were defined as consistently present or consistently absent; minor criteria were characterized as typical, common, or rare. For type A thymomas, we also searched for an atypical variant showing increased mitotic activity (four or more mitosis per 10 high power fields) and coagulative tumor necrosis. For type A and AB thymomas, the component of immature terminal deoxynucleotidyl transferase (TdT)-positive T cells was quantified in three grades, as per ITMIG consensus. 2 Type A thymoma is then defined as grade 1 or 2 in 10% or less of the tumor, and type AB thymoma as grade 2 in more than 10% of the tumor, or as grade 3. For type B3 thymomas ITMIG consensus has not defined major and minor criteria; the criteria that were used are listed in Marx et al. 2 
Immunohistochemistry
If not performed at time of diagnosis, any additional IHC stainings were performed for each subtype accordingly (Supplementary Table 2 ). To overcome difficulties in assessing keratin expression related to the presence of dendritic cells extensions, P63 stainings were used in type B1 and B2 thymomas. CD5 and CD117/KIT expression was assessed on epithelial cells for type B3 thymomas and TCs. Immunostainings for solute carrier family 2 member 1 (GLUT1) were performed in type A and B3 thymomas and in TCs; expression was interpreted as negative (including focal and zonal patterns) or diffuse. 15 Erythrocytes expressing GLUT1 were used as internal positive controls. The cortical (b5T, protease serine 16, and cathepsin V) and medullary (CD40 and claudin 4) markers used in research were not assessed in this study.
Staging
Masaoka-Koga stage was assessed on the basis of ITMIG recommendations by using clinical, imaging, and pathological findings. 8, 13 Stage according to the eighth edition of the TNM staging classification was assessed according to clinical, imaging, and pathological findings.
14 All patients had a systematic lymph node resection as per institutional standards. Surgical resection was classified as complete (R0), microscopically incomplete (R1), or macroscopically incomplete (R2).
Statistical Analyses
All patients were included in the statistical calculations. Categorical variables were compared using the chisquare or Student t test and continuous variables were compared by the Mann-Whitney nonparametric test. A p value less than 0.05 was considered significant. Followup was obtained in all cases and censored on August 15, 2016. Survival was assessed by the Kaplan-Meier method. Time to recurrence (TTR) was calculated from surgical resection to the date of recurrence, with censoring at the date of last follow-up if the patient had not presented with tumor relapse. OS was calculated from surgical resection to the date of death, censoring at the last follow-up date if the patient was alive. Relevant parameters were studied for influence on survival by univariate analysis using the log-rank test. Results were considered significant at the 0.05 level. Statistical analyses were performed using SPSS software, version 17.0 (SPSS. Inc., Chicago, IL).
Results
Patient Characteristics
A total of 188 tumors from 181 patients were included in this study (Table 1 ). There were 89 men (49%) and 92 women (51%); their mean age was 61 years (range 23-85). A total of 57 patients (31%) presented with myasthenia gravis at time of diagnosis. According to the WHO classification, there were nine type A thymomas (5%), 67 type AB thymomas (36%), 19 type B1 thymomas (10%), 46 type B2 thymomas (24%), 27 type B3 thymomas (14%), and 20 TCs (11%). Myasthenia gravis was more frequent in type B2 thymomas (p ¼ 0.002).
Surgical procedure consisted mostly of thymectomy alone for 114 patients (61%); thymectomy was extended to the lung for 26 patients (15%), the pericardium for 21 patients (12%), the mediastinal pleura for three patients (2%), the innominate vein for two patients (1%), and the superior vena cava for one patient (0.5%). Nineteen specimens (10%) were obtained from tumor recurrences. Seventeen cases were biopsy or fragmented specimens (9%). Resection was complete for 138 patients (74%). Median size of the tumor was 6 cm (range 1-22 cm). A median of nine slides per case (range 1-39) were reviewed.
ITMIG Consensus Major and Minor Criteria
After exclusion of 11 necrotic and nonsuitable specimens (two type A thymomas, two type B1 thymomas, two type B3 thymomas, and five TCs), 177 tumor specimens were reviewed for ITMIG consensus major and minor criteria 2 ( Fig. 1) . Major criteria were identified in 100% of type A, AB, B1, and B2 thymomas and 87% of TCs (Fig. 1A-D and F) . The vast majority of TCs (87%) presented with clear-cut atypia and criteria of exclusion of differential diagnosis (see Fig. 1F ). For type B3 thymomas, pink appearance at low magnification, lobular growth, lack of intercellular bridges, and lack of expression of CD117 were present in all cases (Fig. 1E) .
Overall, minor criteria were not consistently observed, as only a minority of our tumors presented with all minor criteria: 0% of seven type A thymomas, 22% of 67 type AB thymomas, 12% of 17 type B1 thymomas, 11% of 46 type B2 thymomas, and 7% of TCs (see Fig. 1A-D and F) . With regard to these criteria, rosettes, glandular formations, subcapsular cysts, and pericytomatous vascular pattern were typical for type A thymomas and were not identified in type B thymomas. Expression of CD20 by epithelial cells was observed in 77% of type AB thymomas and 43% of type A thymomas. Lobular growth pattern was present in all subtypes of TETs with different size of lobules (see Fig. 2A-D) . Perivascular spaces (PVSs) were more frequent in type B thymomas (52% of cases) than in type A and AB thymomas (16%). Medullary islands were rarely identified in type AB and B2 thymomas (19% and 15% of cases, respectively). Expression of GLUT1 was negative in 100% of type A thymomas, negative or nondiffuse in 95% of type B3 thymomas, and extensive in 50% of TCs (see Fig. 2E and F) . Expression of p63 showed scattered nuclei of epithelial cells in type B1 and B2 thymomas in 94% and 87%, respectively (see Fig. 2G-H) , when staining for keratin was positive in all cases.
Qualitative review indicated that there was no atypical variant in type A thymomas and no B3/TC borderline tumor. For type AB thymomas, two morphological patterns were identified: a conventional subtype with typical lymphocyte-poor and lymphocyterich areas in 50 cases (75%) and a metaplastic subtype with pseudofibroblastic cells in 17 cases (25%).
Overall, two cases were classified as TC despite the absence of clear-cut atypia: the first case had an infiltrative growth pattern without organotypic features of thymoma, with positive CD5 and CD117 expression in tumor epithelial cells and negative TdT expression; the second case was infiltrative, with small tumor cell nests within a desmoplastic stroma, without organotypic features of thymoma and CD117, CD5, and solute carrier family 2 member 1 expression on epithelial cells.
Stage according to Masaoka-Koga and the Eighth Edition of the TNM Staging Classification
After exclusion of recurrent cases, fragmented tumors, and biopsy specimens, stage according to Masaoka-Koga and the eighth edition of the TNM staging classification were assessable for 152 patients (Table 2 and Fig. 3 ). Most patients presented with MasaokaKoga stage I tumors (28%) or II tumors (55%), and as expected, 100% of those cases were classified as stage I in the eighth edition of the TNM system (Fig. 3C) . TNM stage II was uncommon (in 2% of cases), including two type B2 thymomas and one TC invading only the pericardium (see Fig. 3C ). Masaoka-Koga stage III tumors accounted for 22 cases (14%); only two (9%) and three (14%) of these were reclassified in the eighth edition of the TNM staging classification, as stage I (in the setting of invasion of the mediastinal pleura) and stage II (in the setting of pericardium invasion), respectively (see Fig. 3C ). None of the tumors were classified as stage IIIb (T4) in the eighth edition of the TNM staging classification. Five cases (3%) were staged as Masaoka-Koga stage IV. Only one case switch (from Masaoka-Koga stage IVb to TNM stage IVa) was observed, and it was related to involvement of perithymic nodes (N1).
Correlation between the WHO classification and the Masaoka-Koga and the eighth edition of the TNM staging classification is shown on Fig. 3A and B. Type B2 and B3 thymomas and TCs presented significantly more frequently with Masaoka-Koga stage III or IV at time of diagnosis (p < 0.001). Such correlation was also observed when correlating WHO histological subtype and TNM stage (p < 0.001).
Patient Outcomes
After a median follow-up of 40 months, only 19 patients (10%) had presented with tumor recurrence, and 10 patients (6%) were dead, eight of whom died of tumor progression. TTR and OS were not significantly different with respect to sex (p ¼ 0.62 and p ¼ 0.46) or presence of myasthenia gravis (p ¼ 0.40 and p ¼ 0.26). Completion of surgical resection was a consistently significant prognostic factor for both TTR and OS (p ¼ 0.005 and p ¼ 0.012, respectively) ( Fig. 4A and B) . WHO histological type was significantly associated with TTR (p ¼ 0.002) (Fig. 4C) . With respect to stage, a higher Masaoka-Koga stage was associated with a poorer TTR (p < 0.001) (Fig. 4E) ; this correlation was no longer observed when the eighth edition of the TNM staging classification was used (p ¼ 0.203) (Fig. 4G) . No significant correlation was observed between OS and histological type (p ¼ 0.096) (Fig. 4D) , Masaoka-Koga stage (p ¼ 0.546) (Fig. 4F) , or stage according to the eighth edition of the TNM staging classification (p ¼ 0.125) (Fig. 4H) . 
Discussion
Taking advantage of the comprehensive analysis of a well-characterized cohort of TETs, our study is the first to highlight the feasibility and relevance for histologic subtyping of the consensus major and minor criteria recently proposed by ITMIG for the WHO classification. 1, 2 Moreover, although we demonstrated for the first time that the well-established correlation between histologic subtype and tumor stage is maintained when switching from the Masaoka-Koga system to the eighth edition of the TNM staging classification, our study suggests that the prognostic significance of the latter system requires further validation in larger cohorts. 13, 14 Our study represents the first independent assessment of ITMIG consensus major and minor criteria on the WHO classification. 2 This consensus was developed after 58 selected instructive cases of resected specimens of TETs had been submitted and reviewed by a group of 18 expert pathologists for establishment of a consensus diagnosis and subsequent identification of major criteria (defined as an absolute requirement or contraindication for a diagnosis) and minor criteria (typical, common, rare, or even exceptional for a given tumor entity and thus supportive of but not required for a diagnosis). 2 Those criteria are reflected in the 2015 WHO classification (fourth edition) not only in the histopathology paragraphs but also in the differential diagnosis paragraphs, with obligatory/indispensable and optional features according to their importance for diagnosis. 3 Our series includes most type AB (36% of cases) and B2 (24% of cases) thymomas; this distribution is similar to that reported in other series, 1,4-6,16,17 except for type A thymomas (which are often more frequent).
As expected given their value in previous classification for thymic tumors, our results indicate that major morphological criteria are observed in 100% of type A, AB, B1, and B2 thymomas. Although major criteria had not been proposed for type B3 thymomas, our results suggest that (1) "pink" impression at low magnification, (2) lack of intercellular bridges, and (3) lack of expression of CD117 by epithelial cells may represent potential major criteria, as these were observed in all of our cases. Still, these criteria are not specific for type B3 thymomas; pink appearance may occur in a rich-epithelial tumor (type A thymomas and TCs) and lack of intercellular bridges and lack of expression if CD117 are useful only in the differential diagnosis between B3 and TC. For TCs, clear-cut atypia was not found in two of our cases (13%); the diagnosis of TC was then retained with association of morphological and immunohistological criteria. The exclusion of differential diagnosis criterion was observed in 100% of cases but may not represent a specific criterion, as it is part of a common diagnostic procedure of all tumors.
The diagnostic value of minor criteria may be more debatable given the variable frequency among our cases. Our first finding is that some minor criteria, including lobular growth pattern in variable size and perivascular spaces, are actually observed across all subtypes; their presence is useful for diagnosis of any TET in the setting of a mediastinal mass. The second finding is that only a few number of tumors may present with all minor criteria (0% of type A thymomas, 22% of type AB thymomas, 12% of type B1 thymomas, 11% of type B2 thymomas, and 7% of TCs), further highlighting the heterogeneity of TETs and ultimately stressing that major criteria, beyond being necessary, may also be sufficient for the subtyping of TETs.
Whether additional minor diagnostic criteria may be included remains debatable; on the basis of our results, we propose that in difficult cases, keratin or p63 IHCl stainings be used to highlight the confluence of epithelial cells in type B1 and B2 thymomas, similarly to TdT staining in type A and AB thymomas for the lymphocytic content. Immunohistochemistry should ultimately be used wisely and on the basis reported panels, 1 weighing the need to assess major and minor criteria when morphological features are challenging 2 with increasing cost of the diagnosis. Encapsulation in type A thymoma may be removed, as we consider this to be a staging criteria. Ultimately, our results highlighting the feasibility and value of the ITMIG consensus major and minor criteria have to be considered in line with proposals made by other academic groups to combine WHO subtypes to increase interobserver reproducibility. [17] [18] [19] In our study, only two observers assessed ITMIG consensus major and minor criteria, and further reproducibility studies are warranted to address potential interobserver variability in this matter. Meanwhile, a recent report of the French nationwide network RYTHMIC on the systematic prospective pathological review of all new cases of TETs diagnosed in France from 2012 to 2014 indicated that when ITMIG consensus criteria are used, discordances between nonexpert diagnosis and expert review may be as low as 22% for histological subtyping. 20 From a clinical standpoint, the clinical and prognostic significance of histological subtyping of thymomas remains to be fully understood and exploited; the recently reported clinical practice guidelines of the European Society for Medical Oncology integrate stage and histological features in the decision making for postoperative radiotherapy on the basis of reported data on recurrence rates and survival of patients. 9 With regard to postoperative radiotherapy, one major issue is how Masaoka stage II and III tumors, which are currently eligible for postoperative radiotherapy according to the guidelines, will be identified among the TNM stage I tumors; histological type-and subtypes for thymomas-may then become a prominent driver. 21 The eighth edition of the TNM staging classification is based on OS analyses of a retrospective international database of more than 10,000 cases. 13, 22 The use of OS as a primary end point may be criticized when thymic tumors often present with multiple episodes of recurrence, usually requiring multidisciplinary management in the setting of chemosensitive and radiosensitive tumors with prolonged survival. 23, 24 In our series, despite a prolonged median follow-up of 40 months, only 6% of patients were dead, thus limiting the power of OS analyses. Moreover, the designation of stage IIIa and IIIb tumors was based on the need to better define resectable and nonresectable cases, respectively, rather than on a significant OS difference. 25 Interestingly, in our surgical cohort, none of our patients were restaged with IIIb disease, highlighting the value of such a proposal in this matter.
Our results highlight the expected switch in staging when moving from the Masaoka-Koga system to the eighth edition of the TNM staging classification toward a majority (84% of our cases) of stage I tumors. Meanwhile, we demonstrated for the first time that the wellestablished, significant correlation between histological subtype and tumor stage, 11, 12, 16 contributing to the prognostic value of the WHO classification, is maintained when switching from the Masaoka-Koga system to the eighth edition of the TNM staging classification. Despite the large number of cases included in our analysis, our data still require validation as the switch toward stage I for most patients reduces the number of patients in the stage III/IV categories, limiting the statistical value of the analyses. In our series, WHO histological type and Masaoka-Koga stage, not TNM stage, were significantly associated with TTR (p ¼ 0.002, p < 0.001, and p ¼ 0.203, respectively). The analysis of larger prospective series is warranted to investigate the actual prognostic value of the eighth edition of the TNM staging classification. Meanwhile, our survival data are in line with previously reported studies. 26 To conclude, the comprehensive analysis of our wellcharacterized cohort of 188 TETs indicates the feasibility and the diagnostic value of the ITMIG consensus statement on WHO histological classification, and it highlights the switch in staging when applying the eighth edition of the TNM staging classification, with possible impact on prognosis assessment and, ultimately, decision making about therapeutic multimodal strategies.
